Notice: Images are for illustration only and may not reflect the exact product you receive. Brand-name medications may look different depending on their country of origin—Canadian versions, for example, often include a "PR" symbol on the packaging. Rest assured, the medication, dosage, and active ingredients will be exactly as prescribed. Canada Pharmacy Store is committed to your health and safety, and we work only with licensed pharmacies to ensure you receive trusted, high-quality medication every time.
General Medication Fact Sheet for Ibrance
| Field | Information |
|---|---|
| Medication Name | Ibrance |
| Generic Name | Palbociclib |
| Purpose | Treatment of HR+, HER2- advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant. |
| Mechanism of Action | Cyclin-dependent kinases (CDK) 4 and 6 inhibitor, leading to cell cycle arrest and decreased tumor growth. |
| Dosage Forms | Oral capsules |
| Available Strengths | 75 mg, 100 mg, 125 mg |
| Dosage Frequency | Once daily for 21 consecutive days, followed by 7 days off, in a 28-day cycle. |
| Common Side Effects | Neutropenia, leukopenia, fatigue, nausea, alopecia, anemia, diarrhea. |
| Serious Side Effects | Infections (including pneumonia), pulmonary embolism, interstitial lung disease/pneumonitis. |
| Drug Interactions | CYP3A inhibitors (e.g., ketoconazole, clarithromycin), CYP3A inducers (e.g., rifampin, phenytoin), grapefruit juice. |
| Important Notes | Monitor blood counts regularly; report signs of infection (e.g., fever, chills) promptly to your healthcare provider. Consult with your doctor for dosage adjustments based on tolerability and lab results. |
| Storage | Store at room temperature between 68°F to 77°F (20°C to 25°C). Protect from moisture. |
| Missed Dose | If a dose is missed, it should not be taken later that day. The next dose should be taken at the regularly scheduled time. |
| Alternatives | Kisqali (ribociclib), Verzenio (abemaciclib), Letrozole, Anastrozole, Tamoxifen. |
Ibrance Alternatives
| Medication | Mechanism of Action | Notes |
|---|---|---|
| Kisqali (ribociclib) | CDK4/6 inhibitor | Used in combination with an aromatase inhibitor or fulvestrant for HR+, HER2- advanced or metastatic breast cancer. |
| Verzenio (abemaciclib) | CDK4/6 inhibitor | Used in combination with endocrine therapy or as monotherapy after prior endocrine therapy for HR+, HER2- advanced or metastatic breast cancer. |
| Letrozole | Aromatase inhibitor | Reduces estrogen levels in postmenopausal women; often used as first-line endocrine therapy. |
| Anastrozole | Aromatase inhibitor | Similar to letrozole; another option for reducing estrogen levels. |
Ibrance Side Effects
| Common Side Effects | Serious Side Effects |
|---|---|
| Neutropenia (low white blood cell count) | Infections (including pneumonia) |
| Leukopenia (low white blood cell count) | Pulmonary embolism |
| Fatigue | Interstitial lung disease/pneumonitis |
| Nausea | Liver problems |
| Alopecia (hair loss) | Severe allergic reactions |
| Anemia (low red blood cell count) | Blood clots |
Ibrance Dosage Guide
| Condition | Starting Dose | Maintenance Dose | Administration Notes |
|---|---|---|---|
| HR+, HER2- Advanced or Metastatic Breast Cancer (with aromatase inhibitor) | 125 mg daily | 125 mg daily for 21 days, followed by 7 days off | Administer orally once daily with food for 21 consecutive days, followed by 7 days off. Repeat cycle every 28 days. Dosage adjustments may be needed based on tolerability. |
| HR+, HER2- Advanced or Metastatic Breast Cancer (with fulvestrant) | 125 mg daily | 125 mg daily for 21 days, followed by 7 days off | Administer orally once daily with food for 21 consecutive days, followed by 7 days off. Repeat cycle every 28 days. Dosage adjustments may be needed based on tolerability. Fulvestrant is administered intramuscularly. |
Ibrance Price With And Without Insurance
| Purchase Context | Estimated Price |
|---|---|
| With Insurance | $500 – $1,000 |
| Without Insurance (U.S.) | $12,000 – $14,000 |
| From Canada | $7,000 |
